SCHEMBL7016271

SCHEMBL7016271

CSc1nc2c(NCc3ccccc3)nc(NCCCO)nc2n1C(C)C

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK1 P06493 15/20 0.65
CDK2 P24941 7/20 0.65
CCNB1 P14635 6/20 0.65
CCNB2 O95067 5/20 0.65
CCNB3 Q8WWL7 5/20 0.65
TDP1 Q9NUW8 3/20 0.65
CDK5 Q00535 3/20 0.56
CSNK1D P48730 1/20 0.56
CLK2 P49760 1/20 0.56
DYRK1A Q13627 1/20 0.56
HIPK4 Q8NE63 1/20 0.56
SRPK1 Q96SB4 1/20 0.56
CLK4 Q9HAZ1 1/20 0.56
CCNE2 O96020 3/20 0.52
CCNA2 P20248 3/20 0.52
CCNE1 P24864 3/20 0.52
CCNA1 P78396 3/20 0.52
KDM4E B2RXH2 2/20 0.52
MAPT P10636 2/20 0.52
ALDH1A1 P00352 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7014201 0.86 CDK1 (0.67) CDK1CDK2CCNB1CCNB2CCNB3
SCHEMBL7099130 0.81 CDK1 (0.69) CDK1CDK2CCNB1CCNB2CCNB3
Bohemine SCHEMBL29572816 0.79 CDK1 (1.00) CDK1CDK2CCNB1CCNB2CCNB3
Bohemine SCHEMBL1443403 0.79 CDK1 (1.00) CDK1CDK2CCNB1CCNB2CCNB3
SCHEMBL3445038 0.79 CDK1 (0.68) CDK1CDK2CCNB1CCNB2CCNB3
SCHEMBL7016096 0.77 CDK2 (0.63) CDK1CDK2CCNB1CCNB2CCNB3
SCHEMBL7112489 0.76 CDK1 (0.94) CDK1CDK2CCNB1CCNB2CCNB3
SCHEMBL7113555 0.75 CDK1 (0.92) CDK1CDK2CCNB1CCNB2CCNB3
SCHEMBL14182620 0.75 CDK1 (0.87) CDK1CDK2CCNB1CCNB2CCNB3
SCHEMBL1216905 0.72 CDK1 (1.00) CDK1CDK2CCNB1CCNB2CCNB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030191086-A1 Substituted nitrogen heterocyclic derivatives and pharmaceutical use thereof USTAV EXPERIMENTALNI BOTANIKY AV CR 2003-10-09 US disclosed
EP-1147108-B1 SUBSTITUTED NITROGEN HETEROCYCLIC DERIVATIVES AND PHARMACEUTICAL USE THEREOF USTAV EX BOTAN AKADEMIE VED CE (CZ) 2003-08-13 EP disclosed
US-6552192-B1 Inhibiting cyclin dependent kinase proteins, viruses, and immunostimulation; antimitotic, antiviral, anticancinogenic, antidegenerative, immunosuppressive USTAU EXPERIMENTALNI BOTANIKY AV-CR (CZ) 2003-04-22 US disclosed
EP-1147108-A1 SUBSTITUTED NITROGEN HETEROCYCLIC DERIVATIVES AND PHARMACEUTICAL USE THEREOF Ustav Experimentalni Botaniky Akademie ved Ceské Republiky (CZ) 2001-10-24 EP disclosed
WO-2000043394-A1 SUBSTITUTED NITROGEN HETEROCYCLIC DERIVATIVES AND PHARMACEUTICAL USE THEREOF ÚSTAV EXPERIMENTÁLNÍ BOTANIKY AV CR (CZ) 2000-07-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030191086-A1 Substituted nitrogen heterocyclic derivatives and pharmaceutical use thereof CDK4, CDK5, CCNI CDK1 6/4885CDK2 11/4885CCNB1 63/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.